Loading
CCND2 (G1/S-specific cyclin-D2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Skin cancer and 4 more.
Regulatory component of the cyclin D2-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase.
CIViC holds 7 clinical evidence items and 0 assertions across 3 variants, naming Palbociclib. Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes literature 0.99, affected pathway 0.69, genetic association 0.60, somatic mutation 0.85). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Acute Myeloid Leukaemia, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma.
In plain words · CCND2 (G1/S-specific cyclin-D2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Skin cancer and 4 more.
CCND2 (G1/S-specific cyclin-D2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Skin cancer and 4 more.
Regulatory component of the cyclin D2-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition.
No product in this corpus aims at CCND2 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CCND2: RNA tissue enhanced (heart muscle 28 nTPM); no normal tissue stained high; highest cancer staining thyroid cancer (2 of 4 high). Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Skin cancer (all types), Lung cancer (all types), Leukaemia); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P30279; CIViC gene CCND2; IntOGen CCND2; Human Protein Atlas CCND2 tissue; Open Targets ENSG00000118971 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Xiong et al, Genomics, 1992, "Molecular cloning and chromosomal mapping of CCND genes encoding human D-type cyclins". Source.
Sources: HGNC HGNC:1583 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P30279 (protein name, function text, keywords and locations (REST API)); CIViC gene CCND2 (7 evidence items, 0 assertions, 3 variants; diseases: Stomach Cancer, Lung Squamous Cell Carcinoma, Cancer (GraphQL API, CC0)); Open Targets ENSG00000118971 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: colorectal cancer 0.59, melanoma 0.56, skin cancer 0.55 (GraphQL API, CC0)); IntOGen CCND2 (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Regulatory component of the cyclin D2-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Location: Nucleus; Cytoplasm; Nucleus membrane (UniProt). Locus 12p13.32 (HGNC).
RNA: tissue enhanced (heart muscle 28 nTPM), detected in many normal tissues.
No normal tissue stained high; medium in Epididymis, Heart muscle, Rectum, Thyroid gland.
RNA cancer enhanced: Testicular Germ Cell Tumor 77 pTPM.
Medium only: breast cancer, endometrial cancer, lung cancer, lymphoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CCND2" OR ABSTRACT:"CCND2" OR TITLE:"cyclin D2" OR ABSTRACT:"cyclin D2" OR TITLE:"G1/S-specific cyclin-D2" OR ABSTRACT:"G1/S-specific cyclin-D2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CCND2, not a curated reading list.